产品
编 号：F419579
分子式：C19H35N
分子量：277.49
分子式：C19H35N
分子量：277.49
产品类型
规格
价格
是否有货
结构图
CAS No: 6621-47-2
产品详情
生物活性：
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina.
体内研究：
Perhexiline (200 mg/kg, p.o., daily for 8 weeks) reduces peripheral neural function in female DA rats.Perhexiline (80 mg/kg, oral gavage, for 3 days) demonstrates anti-tumor activity in glioblastoma mouse model.Animal Model:Orthotopic glioblastoma mouse model
Dosage:80 mg/kg
Administration:Oral gavage, for 3 days.
Result:Reduces tumor size (MR imaging) and improves in overall survival.
体外研究：
Perhexiline (5-25 μM, 2-6 h) reduces cell viability in HepG2 cells.Perhexiline (5-25 μM, 2-6 h) reduces cellular ATP content and Lactate dehydrogenase (LDH) release in HepG2 cells.Perhexiline (20 μM, 2 h) activates caspase 3/7 in HepG2 cells.Perhexiline (5-25 μM, 4 h) causes mitochondrial dysfunction in HepG2 cells.Perhexiline (5 μM, 48 h) selectively induces massive apoptosis in CLL cells (high expression of CPT).
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina.
体内研究：
Perhexiline (200 mg/kg, p.o., daily for 8 weeks) reduces peripheral neural function in female DA rats.Perhexiline (80 mg/kg, oral gavage, for 3 days) demonstrates anti-tumor activity in glioblastoma mouse model.Animal Model:Orthotopic glioblastoma mouse model
Dosage:80 mg/kg
Administration:Oral gavage, for 3 days.
Result:Reduces tumor size (MR imaging) and improves in overall survival.
体外研究：
Perhexiline (5-25 μM, 2-6 h) reduces cell viability in HepG2 cells.Perhexiline (5-25 μM, 2-6 h) reduces cellular ATP content and Lactate dehydrogenase (LDH) release in HepG2 cells.Perhexiline (20 μM, 2 h) activates caspase 3/7 in HepG2 cells.Perhexiline (5-25 μM, 4 h) causes mitochondrial dysfunction in HepG2 cells.Perhexiline (5 μM, 48 h) selectively induces massive apoptosis in CLL cells (high expression of CPT).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备